Display options
Cite
Wang W, Lv FF, Du Y, et al. The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis. Cancer Cell Int. 2015;15:10doi: 10.1186/s12935-015-0158-4.
Wang, W., Lv, F. F., Du, Y., Li, N., Chen, Y., & Chen, L. (2015). The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis. Cancer cell international, 1510. https://doi.org/10.1186/s12935-015-0158-4
Wang, Wei, et al. "The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis." Cancer cell international vol. 15 (2015): 10. doi: https://doi.org/10.1186/s12935-015-0158-4
Wang W, Lv FF, Du Y, Li N, Chen Y, Chen L. The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis. Cancer Cell Int. 2015 Feb 04;15:10. doi: 10.1186/s12935-015-0158-4. eCollection 2015. PMID: 25698901; PMCID: PMC4334604.
Copy Download .nbib Format: NLM
Share it on

Cancer Cell Int. 2015 Feb 04;15:10. doi: 10.1186/s12935-015-0158-4. eCollection 2015.

The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis.

Cancer cell international

Wei Wang, Fei-Fei Lv, Yan Du, Nannan Li, YaLing Chen, LiHong Chen

Affiliations

  1. Department of Hematology, Southeast Hospital Affiliated to Xiamen University (the 175th Hospital of Chinese PLA), NO.269, Zhanghua Middle Road, Zhangzhou, Fujian 363000 China.

PMID: 25698901 PMCID: PMC4334604 DOI: 10.1186/s12935-015-0158-4

Abstract

AIM: To determine the effects of arsenic trioxide (ATO) and nilotinib (AMN107, Tasigna) alone or in combination on the proliferation and differentiation of primary leukemic cells from patients with chronic myeloid leukemia in the blast crisis phase (CML-BC).

METHODS: Cells were isolated from the bone marrow of CML-BC patients and were treated with 1 μM ATO and 5 nM nilotinib, either alone or in combination. Cell proliferation was evaluated using a MTT assay. Cell morphology and the content of hemoglobin were examined with Wright-Giemsa staining and benzidine staining, respectively. The expression of cell surface markers was determined using flow cytometric analysis. The levels of mRNA and protein were analyzed using RT-PCR and Western blotting, respectively.

RESULTS: ATO and nilotinib alone or in combination suppressed cell proliferation in a dose- and time-dependent pattern (P < 0.01 vs. control). Drug treatments promoted erythroid differentiation of CML-BC cells, with a decreased nuclei/cytoplasm ratio but increased hemoglobin content and glycophorin A (GPA) expression (P < 0.01 compared with control). In addition, macrophage and granulocyte lineage differentiation was also induced after drug treatment. The mRNA and protein levels of basic helix-loop-helix (bHLH) transcription factor T-cell acute lymphocytic leukemia protein 1 (TAL1) and B cell translocation gene 1 (BTG1) were both upregulated after 3 days of ATO and Nilotinib treatment.

CONCLUSIONS: Our findings indicated that ATO and nilotinib treatment alone or in combination greatly suppressed cell proliferation but promoted the differentiation of CML-BC cells towards multiple-lineages. Nilotinib alone preferentially induced erythroid differentiation while combined treatment with ATO preferentially induced macrophage and granulocyte lineage differentiation.

Keywords: AMN107; Arsenic trioxide; CML-BC; Differentiation; Nilotinib; Proliferation

References

  1. Blood. 2011 Jun 16;117(24):6425-37 - PubMed
  2. Br J Cancer. 2006 Jun 19;94(12):1765-9 - PubMed
  3. J Clin Invest. 2010 Jul;120(7):2254-64 - PubMed
  4. Cancer Res. 2011 Apr 15;71(8):2838-47 - PubMed
  5. J Cell Biol. 2004 Jan 19;164(2):175-84 - PubMed
  6. J Clin Oncol. 2009 Sep 1;27(25):4204-10 - PubMed
  7. Blood. 2002 May 15;99(10):3547-53 - PubMed
  8. Oncol Rep. 2003 May-Jun;10(3):705-9 - PubMed
  9. Blood. 2004 Jun 1;103(11):4010-22 - PubMed
  10. Eur J Cancer. 2002 Sep;38 Suppl 5:S19-27 - PubMed
  11. EMBO J. 1992 Nov;11(11):4073-81 - PubMed
  12. Blood. 2008 Feb 15;111(4):1834-9 - PubMed
  13. J Clin Oncol. 2005 Apr 1;23(10):2396-410 - PubMed
  14. Blood. 1993 Feb 1;81(3):647-55 - PubMed
  15. Blood. 2002 Mar 15;99(6):1928-37 - PubMed
  16. Zhonghua Xue Ye Xue Za Zhi. 2012 Jun;33(6):453-6 - PubMed
  17. Leuk Res. 2013 Oct;37(10 ):1309-14 - PubMed
  18. Blood. 2007 Nov 15;110(10):3540-6 - PubMed
  19. Int J Environ Res Public Health. 2006 Jun;3(2):136-40 - PubMed
  20. Blood. 2006 Nov 1;108(9):2998-3004 - PubMed
  21. Int J Cancer. 2014 Feb 15;134(4):988-96 - PubMed
  22. Cancer Res. 2002 Jul 15;62(14):3893-903 - PubMed
  23. Curr Opin Genet Dev. 2006 Feb;16(1):92-9 - PubMed
  24. Blood. 2002 May 15;99(10):3530-9 - PubMed
  25. Clin Cancer Res. 2005 Jul 1;11(13):4941-7 - PubMed
  26. Clin Cancer Res. 2002 Jul;8(7):2167-76 - PubMed
  27. J Biochem Mol Biol. 2002 Jul 31;35(4):377-83 - PubMed

Publication Types